Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Jennings Headshot
Talking Therapeutics
Dissecting the New 2023 AFib Guidelines
01/10/2024
In this installment of Talking Therapeutics, Douglas Jennings highlights some of the more significant recommendations from the new 2023 atrial fibrillation treatment guidelines released by the American College of Cardiology and American Heart...
In this installment of Talking Therapeutics, Douglas Jennings highlights some of the more significant recommendations from the new 2023 atrial fibrillation treatment guidelines released by the American College of Cardiology and American Heart...
In this installment of Talking...
01/10/2024
Pharmacy Learning Network
Commentary
Save Those Kidney Beans: Nephroprotective Effects of Finerenone for Patients With Diabetes
06/07/2021
In a past Talking Therapeutics column, Dr Jennings opined the nephroprotective effects of SGL2 inhibitors for patients with CKD. In this week’s column, he continues the kidney-focused theme with an exposé on finerenone—a novel, highly...
In a past Talking Therapeutics column, Dr Jennings opined the nephroprotective effects of SGL2 inhibitors for patients with CKD. In this week’s column, he continues the kidney-focused theme with an exposé on finerenone—a novel, highly...
In a past Talking Therapeutics...
06/07/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
Take a Pause on Platelet-Rich Plasma
12/01/2021
In this week's installment of Talking Therapeutics, Dr Jennings showcases platelet-rich plasma for the treatment of musculoskeletal conditions, including its theoretical uses and efficacy data.
In this week's installment of Talking Therapeutics, Dr Jennings showcases platelet-rich plasma for the treatment of musculoskeletal conditions, including its theoretical uses and efficacy data.
In this week's installment of...
12/01/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
Battling BA.5: How Do Monoclonals and Drug Therapies Stack Up?
07/28/2022
Dr Jennings reviews a new study evaluating the efficacy of COVID-19 treatments against the BA.5 variant in a laboratory setting.
Dr Jennings reviews a new study evaluating the efficacy of COVID-19 treatments against the BA.5 variant in a laboratory setting.
Dr Jennings reviews a new study...
07/28/2022
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
Can Dexmedetomidine Prevent Atrial Fibrillation?
05/05/2023
Dr Jennings reviews new research into whether the use of dexmedetomidine, a sedative commonly administered in intensive care units, was associated with a reduction in new-onset atrial fibrillation.
Dr Jennings reviews new research into whether the use of dexmedetomidine, a sedative commonly administered in intensive care units, was associated with a reduction in new-onset atrial fibrillation.
Dr Jennings reviews new research...
05/05/2023
Pharmacy Learning Network
Jennings Headshot
Talking Therapeutics
Another Dangerous DOAC Drug Interaction
05/09/2024
In this installment of Talking Therapeutics, Dr Jennings explores another potentially dangerous direct-acting oral anticoagulant (DOAC) combination based on a recent study.
In this installment of Talking Therapeutics, Dr Jennings explores another potentially dangerous direct-acting oral anticoagulant (DOAC) combination based on a recent study.
In this installment of Talking...
05/09/2024
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
ACC Updates Part 2
06/01/2021
Last week’s edition of Talking Therapeutics highlighted several new and exciting studies related to heart failure drug therapies. This week we tackle three more pivotal trials from this year’s exciting conference.
Last week’s edition of Talking Therapeutics highlighted several new and exciting studies related to heart failure drug therapies. This week we tackle three more pivotal trials from this year’s exciting conference.
Last week’s edition of Talking...
06/01/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
Going Gaga for GLP-1 Agonists
02/23/2022
In Dr Jennings' newest Talking Therapeutics column, he reviews the latest data on GLP-1 agonists and SGLT2 inhibitors for the reduction of cardiovascular disease risk among patients with diabetes.
In Dr Jennings' newest Talking Therapeutics column, he reviews the latest data on GLP-1 agonists and SGLT2 inhibitors for the reduction of cardiovascular disease risk among patients with diabetes.
In Dr Jennings' newest Talking...
02/23/2022
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
Time to Divorce Bleeding From Thrombosis
09/08/2021
This week, Dr Jennings explores the science behind a novel anticoagulant therapy, and explains why emerging clinical trial data helps demonstrate the promise for a treatment to decouple bleeding from thrombosis.
This week, Dr Jennings explores the science behind a novel anticoagulant therapy, and explains why emerging clinical trial data helps demonstrate the promise for a treatment to decouple bleeding from thrombosis.
This week, Dr Jennings explores...
09/08/2021
Pharmacy Learning Network
Headshot and logo for Talking Therapeutics with Douglas Jennings, PharmD
Talking Therapeutics
A New Game Changer for HFpEF
09/06/2023
This week, Dr Jennings reviews a new study that evaluated the effect of semaglutide in patients categorized as obese with heart failure with a preserved ejection fraction.
This week, Dr Jennings reviews a new study that evaluated the effect of semaglutide in patients categorized as obese with heart failure with a preserved ejection fraction.
This week, Dr Jennings reviews a...
09/06/2023
Pharmacy Learning Network

Upcoming Events

February 2 ⁠–⁠ February 5
LLM Winter Symposium
February 7 ⁠–⁠ February 9
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
GD Solid Tumors
March 22 ⁠–⁠ March 23
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use